PFE vs XOM: Which Is the Better Buy?
Side-by-side comparison of Pfizer Inc. and Exxon Mobil Corporation — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-04-11.
Pfizer Inc. · Healthcare
$26.91
+30.1% upside to fair value
Med Conviction
Grade B+
VS
Exxon Mobil Corporation · Energy
$152.30
-33.0% upside to fair value
Med Conviction
Grade C+
QuantHub Verdict
PFE has more upside to fair value
(+30.1%).
PFE trades at a lower forward P/E
(9.5x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
PFE |
XOM |
| Current Price |
$26.91 |
$152.30 |
| Fair Value Estimate |
$35.00 |
$102.00 |
| Upside to Fair Value |
+30.1%
|
-33.0%
|
| Market Cap |
$153.0B |
$634.6B |
| Forward P/E |
9.5x
|
17.5x
|
| EV / EBITDA |
13.8x
|
9.8x
|
| Price / Sales |
2.4x
|
2.0x
|
| Price / FCF |
16.8x
|
26.9x
|
| Revenue Growth YoY |
-1.6%
|
-4.5%
|
| Gross Margin |
70.3%
|
21.7%
|
| Operating Margin |
24.7%
|
10.5%
|
| Return on Equity |
9.0%
|
11.1%
|
| Dividend Yield |
6.4% |
2.65% |
| FCF Yield |
5.9%
|
3.72%
|
| Analyst Consensus |
Hold
|
Buy
|
Investment Thesis
Pfizer remains the world's largest traditional pharmaceutical company by non-COVID revenue, generating $62.6B in 2025 sales across oncology, cardiovascular, immunology, and vaccines. The stock trades at a P/S of 2.44x, still well below the 5-year median of 3.10x, driven by post-COVID revenue normalization, a $17-18B patent cliff spanning 2026-2028, and $61.6B in acquisition-related debt from Seag…
Exxon Mobil is a world-class integrated energy supermajor with unmatched Permian Basin scale following the Pioneer Natural Resources acquisition, a high-margin Guyana growth engine, and disciplined capital allocation. However, the stock remains significantly overvalued relative to its own 5-year history on every key metric. At $152, XOM trades at roughly 22x trailing earnings, 1.96x sales, and 27…
Accumulation Zones
| Metric |
PFE |
XOM |
| Zone Low |
$25.00 |
$77.00 |
| Zone High |
$29.00 |
$92.00 |
| In Buy Zone? |
Yes
|
No
|